Hexiris Welcomes Paul Sowyrda and Steven Schiffman to Its Board of Directors [Yahoo! Finance]
Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ:AMEX Investor Relations:
ir.citiuspharma.com
Company Research
Source: Yahoo! Finance
company dedicated to developing innovative, accessible, and effective ophthalmic solutions for patients and community ophthalmologists, is pleased to announce the appointment of Paul Sowyrda and Steven Schiffman to its Board of Directors. Hex_photo Board Hexiris Welcomes Paul Sowyrda and Steven Schiffman to Its Board of Directors Strategic Growth for Hexiris “We are thrilled to welcome Paul Sowyrda and Steven Schiffman to our Board. Their extensive industry knowledge and proven expertise in strategic foresight, investment strategy, and corporate leadership will play a pivotal role in driving Hexiris' growth and advancing its mission to address critical unmet needs in ophthalmology worldwide,” said Houfar Sekhavat, Co-Founder, Chairman and Co-CEO of Hexiris. Paul Sowyrda: A Visionary in Biopharmaceutical and Medical Device Development With over 25 years of experience in the life sciences industry, Paul Sowyrda has demonstrated leadership across every phase of development.
Show less
Read more
Impact Snapshot
Event Time:
CTXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTXR alerts
High impacting Citius Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CTXR
News
- Citius Pharmaceuticals (NASDAQ:CTXR) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $6.00 price target on the stock.MarketBeat
- Citius Pharmaceuticals (NASDAQ:CTXR) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq RulesPR Newswire
- Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq RulesPR Newswire
- Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences [Yahoo! Finance]Yahoo! Finance
CTXR
Earnings
- 5/14/25 - Beat
CTXR
Sec Filings
- 12/1/25 - Form 8-K
- 10/27/25 - Form SCHEDULE
- 10/23/25 - Form 8-K
- CTXR's page on the SEC website